Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients

NCT01934452 · clinicaltrials.gov ↗

COMPLETED

Status

77

Enrollment

INDUSTRY

Sponsor class

Conditions

Complete Remission in Renal Cell Carcinoma

Interventions

DRUG: sunitinib
DRUG: sunitinib

Sponsor

Pfizer